Clinical Trial Update: WBRT & Erlotinib in Advanced NSCLC and Brain Metastases [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating whole-brain radiotherapy with erlotinib in patients with advanced non-small cell lung cancer and brain metastases was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib) (erlotinib)

Snippet

Sponsor: University College, London | Conditions: Lung Cancer, Metastatic Cancer | Phase 2 | Status: TERMINATED